<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01790698</url>
  </required_header>
  <id_info>
    <org_study_id>INFECT-FP7305340</org_study_id>
    <nct_id>NCT01790698</nct_id>
  </id_info>
  <brief_title>Systems Medicine to Study Necrotizing Soft Tissue Infections (NSTIs).</brief_title>
  <acronym>INFECT</acronym>
  <official_title>Improving Outcome of Necrotizing Fasciitis: Elucidation of Complex Host and Pathogen Signatures That Dictate Severity of Tissue Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blekinge County Council Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bergen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helmholtz Centre for Infection Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wageningen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>LifeGlimmer GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anagnostics Bioanalysis GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lee Spark NF Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tel Aviv University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This proposal focuses on highly lethal destructive tissue infections, i.e. necrotizing&#xD;
      fasciitis and other necrotizing soft tissue infections (NSTIs), which are associated with&#xD;
      high morbidity and mortality. The fulminant course of NSTIs demands immediate diagnosis and&#xD;
      adequate interventions in order to salvage lives and limbs. However, diagnosis and management&#xD;
      are difficult due to heterogeneity in clinical presentation, in co-morbidities and in&#xD;
      microbiological aetiology. Thus, there is an urgent need for novel diagnostics and&#xD;
      therapeutics in order to improve outcome of NSTIs. A comprehensive knowledge of diagnostic&#xD;
      features, causative microbial agent, treatment strategies, and pathogenic mechanisms (host&#xD;
      and bacterial disease traits and their underlying interaction network) is required for an&#xD;
      improved diagnosis and management of NSTIs. The current proposal is designed to obtain such&#xD;
      insights through an integrated systems biology approach in patients and experimental models.&#xD;
      The project is based on a prospective NSTI patients cohort including a clinical registry to&#xD;
      document clinical data and treatment strategies, combined with an isolate and biobank&#xD;
      collection. The samples will be analyzed through advanced bioinformatics and computational&#xD;
      modelling work flow to identify and quantify pathogen signatures and underlying networks that&#xD;
      contribute to disease outcome. One aim is to translate clinical and systems biology data into&#xD;
      development of novel diagnostics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be prospectively recruited at 5 clinical centers (Rigshospitalet, Karolinska&#xD;
      University Hospital, Blekinge University, Sahlgrenska University and University of Bergen).&#xD;
      Clinical definition criteria for NSTI: NSTI is a clinical diagnosis. Initial signs are the&#xD;
      occurrence of erythema, pain or tenderness beyond margins of erythema and swelling. Imaging&#xD;
      and laboratory tests have little predictive value in the early stage. The gold standard&#xD;
      modality for diagnosis of NSTI remains operative exploration. Operative findings that are&#xD;
      consistent with NSTI include &quot;dishwater or foul smelling discharge, necrosis or lack of&#xD;
      bleeding and loss of the normal resistance of the fascia to finger dissection. A patient&#xD;
      admitted for critical care and / or surgery due to severe soft tissue infection of the&#xD;
      fascia, muscle or subcutaneous tissues will be enrolled in this NSTI study. The patients will&#xD;
      be stratified based on several clinical parameters including among others SAPS score,&#xD;
      presence of multiorgan failure, and hypotensive shock. This stratification serves to classify&#xD;
      the patients in defined severity classes to be used in analyses and modeling. Detailed&#xD;
      demographic and clinical information will be documented in the interactive database&#xD;
      including: age, gender, medical history, clinical presentation (shock, multiorgan failure&#xD;
      etc), treatment and outcome. Disease progress: The clinical database is to contain&#xD;
      information on the spread of the infection at the different times of inspection/surgical&#xD;
      intervention. Severity of the infections will be documented by use of the updated CREST&#xD;
      classification scheme, SAPS III score, and the LRINEC score. Detailed information regarding&#xD;
      antimicrobial therapy, surgical intervention, innovative therapy (IVIG and HBO) will be&#xD;
      documented.&#xD;
&#xD;
      Samples will be collected from all enrolled patients. Standard operating procedures will be&#xD;
      generated and implemented at all sites to ensure a quality assured collection and handling of&#xD;
      samples. Samples to be collected include (a) isolates, (b) blood samples to be processed for&#xD;
      DNA, RNA and plasma/cells and (c) tissue biopsies in all patients whenever surgical&#xD;
      interventions are indicated. The samples will be analyzed using genomics, transcriptomics,&#xD;
      metabolomics and proteomics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">January 2018</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Prognostic/diagnostic value (ROC curves: specificity, sensitivity, predictive values) of classification and severity scores in NSTIs</measure>
    <time_frame>3 months - further oservation up to 24 month may apply</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of IVIG and HBO-therapy on mortality rates in matched (defined by severity scores and aetiology) NSTI patients</measure>
    <time_frame>3 months - further observation up to 24 month may apply</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of hypotension, multiorgan failure, or fatal outcome of NSTI in relation to microbiologic aetiology</measure>
    <time_frame>3 months - further observation up to 60 month may apply</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">409</enrollment>
  <condition>Soft Tissue Infections</condition>
  <condition>Necrotizing Fasciitis</condition>
  <condition>Necrotizing Soft Tissue Infections</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Bacterial isolates, whole blood, plasma, tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized patients with NSTI&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Necrotizing soft tissue infections&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients under the age of 18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Bergen</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>SE-416 50</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blekinge Hospital</name>
      <address>
        <city>Karlskrona</city>
        <zip>SE-371 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>February 4, 2013</study_first_submitted>
  <study_first_submitted_qc>February 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2013</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Anna Norrby-Teglund</investigator_full_name>
    <investigator_title>Professor, Coordinator of INFECT</investigator_title>
  </responsible_party>
  <keyword>Necrotizing fasciitis</keyword>
  <keyword>Streptococcus pyogenes</keyword>
  <keyword>Staphylococcus aureus</keyword>
  <keyword>Immunopathogenesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Soft Tissue Infections</mesh_term>
    <mesh_term>Fasciitis</mesh_term>
    <mesh_term>Fasciitis, Necrotizing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

